TLC, a Taiwan novel drug developer, was approved to begin US trials of an oncology drug (TLC178), a lipid-encapsulated form of vinorelbine. Using its NanoX™ nanotechnology platform, TLC devised the lipid delivery formulation with the goal of targeting the chemotherapy and lowering its toxicity. TLC hopes the technology will increase the indications for TLC178 beyond non-small cell lung cancer (NSCLC) to lymphomas and other advanced solid tumors.
